JP2015524798A5 - - Google Patents

Download PDF

Info

Publication number
JP2015524798A5
JP2015524798A5 JP2015521836A JP2015521836A JP2015524798A5 JP 2015524798 A5 JP2015524798 A5 JP 2015524798A5 JP 2015521836 A JP2015521836 A JP 2015521836A JP 2015521836 A JP2015521836 A JP 2015521836A JP 2015524798 A5 JP2015524798 A5 JP 2015524798A5
Authority
JP
Japan
Prior art keywords
amino
cyano
imidazo
chloro
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015521836A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015524798A (ja
JP6228199B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/050247 external-priority patent/WO2014011974A1/en
Publication of JP2015524798A publication Critical patent/JP2015524798A/ja
Publication of JP2015524798A5 publication Critical patent/JP2015524798A5/ja
Application granted granted Critical
Publication of JP6228199B2 publication Critical patent/JP6228199B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015521836A 2012-07-13 2013-07-12 キナーゼ阻害剤として有用であるイミダゾトリアジンカルボニトリル Expired - Fee Related JP6228199B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261671179P 2012-07-13 2012-07-13
US61/671,179 2012-07-13
US201361790511P 2013-03-15 2013-03-15
US61/790,511 2013-03-15
PCT/US2013/050247 WO2014011974A1 (en) 2012-07-13 2013-07-12 Imidazotriazinecarbonitriles useful as kinase inhibitors

Publications (3)

Publication Number Publication Date
JP2015524798A JP2015524798A (ja) 2015-08-27
JP2015524798A5 true JP2015524798A5 (https=) 2016-07-21
JP6228199B2 JP6228199B2 (ja) 2017-11-08

Family

ID=48833089

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015521836A Expired - Fee Related JP6228199B2 (ja) 2012-07-13 2013-07-12 キナーゼ阻害剤として有用であるイミダゾトリアジンカルボニトリル

Country Status (22)

Country Link
US (4) US9273057B2 (https=)
EP (1) EP2872514B1 (https=)
JP (1) JP6228199B2 (https=)
KR (1) KR20150059647A (https=)
CN (1) CN104470925B (https=)
AR (1) AR092349A1 (https=)
AU (1) AU2013290054A1 (https=)
BR (1) BR112015000704A2 (https=)
CA (1) CA2878852A1 (https=)
CL (1) CL2015000094A1 (https=)
CO (1) CO7180199A2 (https=)
EA (1) EA201590224A1 (https=)
HK (1) HK1210775A1 (https=)
IL (1) IL236605A0 (https=)
MX (1) MX2015000310A (https=)
PE (1) PE20150332A1 (https=)
PH (1) PH12015500064B1 (https=)
SG (1) SG11201500158RA (https=)
TN (1) TN2015000002A1 (https=)
TW (1) TW201414737A (https=)
WO (1) WO2014011974A1 (https=)
ZA (1) ZA201501009B (https=)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2680741A1 (en) 2007-03-22 2009-01-15 The Regents Of The University Of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
WO2010014854A2 (en) 2008-07-31 2010-02-04 The Regents Of The University Of California Antibodies that neutralize botulinum neurotoxins
US9243057B2 (en) 2010-08-31 2016-01-26 The Regents Of The University Of California Antibodies for botulinum neurotoxins
LT2841437T (lt) 2012-04-26 2017-09-11 Bristol-Myers Squibb Company Imidazotiadiazolo ir imidazopirazino dariniai, kaip proteazės aktyvuotų receptorių 4 (par4) inhibitoriai, skirti trombocitų agregacijos gydymui
TWI568722B (zh) 2012-06-15 2017-02-01 葛蘭馬克製藥公司 作爲mPGES-1抑制劑之三唑酮化合物
TW201414737A (zh) 2012-07-13 2014-04-16 必治妥美雅史谷比公司 作爲激酶抑制劑之咪唑并三□甲腈
JP6437452B2 (ja) 2013-01-14 2018-12-12 インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation Pimキナーゼ阻害剤として有用な二環式芳香族カルボキサミド化合物
RS60244B1 (sr) 2013-01-15 2020-06-30 Incyte Holdings Corp Jedinjenja tiazolkarboksamida i piridinkarboksamida korisna kao inhibitori pim kinaze
UY35464A (es) 2013-03-15 2014-10-31 Araxes Pharma Llc Inhibidores covalentes de kras g12c.
CN105658653A (zh) 2013-08-23 2016-06-08 因赛特公司 可用作pim激酶抑制剂的呋喃并-和噻吩并-吡啶甲酰胺化合物
TWI659021B (zh) 2013-10-10 2019-05-11 亞瑞克西斯製藥公司 Kras g12c之抑制劑
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016010897A1 (en) 2014-07-14 2016-01-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
DE102014111834A1 (de) * 2014-08-19 2016-02-25 Illinois Tool Works Inc. Einfülleinrichtung für einen Betriebsstofftank
JP2018513853A (ja) 2015-04-10 2018-05-31 アラクセス ファーマ エルエルシー 置換キナゾリン化合物およびその使用方法
WO2016196244A1 (en) 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
TWI734699B (zh) 2015-09-09 2021-08-01 美商英塞特公司 Pim激酶抑制劑之鹽
EP3356353A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
WO2017058915A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
US10882847B2 (en) 2015-09-28 2021-01-05 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
WO2017058807A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
US9920032B2 (en) 2015-10-02 2018-03-20 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
WO2017070135A1 (en) * 2015-10-20 2017-04-27 Bristol-Myers Squibb Company Prodrugs of 2-(4-(3-((4-amino-7-cyano-imidazo[2,1-f][1,2,4]triazin-2-yl)amino)phenyl)piperaz in-1-yl)propanamide derivatives as ck2 inhibitors for the treatment of cancer
WO2017070137A1 (en) * 2015-10-20 2017-04-27 Bristol-Myers Squibb Company Combination of ck2 inhibitors and immune checkpoint modulators for cancer treatment
KR20180081596A (ko) 2015-11-16 2018-07-16 아락세스 파마 엘엘씨 치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법
WO2017223432A1 (en) 2016-06-24 2017-12-28 Polaris Pharmaceuticals Ck2 inhibitors, compositions and methods thereof
WO2017223414A1 (en) 2016-06-24 2017-12-28 Incyte Corporation HETEROCYCLIC COMPOUNDS AS PI3K-γ INHIBITORS
WO2018140514A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
WO2018140513A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
EP3573954A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
WO2018140599A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc Benzothiophene and benzothiazole compounds and methods of use thereof
CN110382482A (zh) 2017-01-26 2019-10-25 亚瑞克西斯制药公司 稠合的杂-杂二环化合物及其使用方法
US11639346B2 (en) 2017-05-25 2023-05-02 Araxes Pharma Llc Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS
AU2018271990A1 (en) 2017-05-25 2019-12-12 Araxes Pharma Llc Covalent inhibitors of KRAS
WO2019051469A1 (en) * 2017-09-11 2019-03-14 Krouzon Pharmaceuticals, Inc. Octahydrocyclopenta[c]pyrrole allosteric inhibitors of shp2
AR113922A1 (es) 2017-12-08 2020-07-01 Incyte Corp Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
MX2021000887A (es) 2018-08-01 2021-03-31 Araxes Pharma Llc Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer.
WO2020086739A1 (en) * 2018-10-24 2020-04-30 Araxes Pharma Llc 2-(2-acryloyl-2,6-diazaspiro[3.4]octan-6-yl)-6-(1h-indazol-4-yl)-benzonitrile derivatives and related compounds as inhibitors of g12c mutant kras protein for inhibiting tumor metastasis
AR119494A1 (es) * 2019-07-29 2021-12-22 Servier Lab DERIVADOS DE 6,7-DIHIDRO-5H-PIRIDO[2,3-c]PIRIDAZIN-8-ILO, COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN Y SUS USOS COMO AGENTES PROAPOPTÓTICOS
US12478624B2 (en) 2019-10-02 2025-11-25 Tolremo Therapeutics Ag Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer
IL299344A (en) 2020-06-25 2023-02-01 Tolremo Therapeutics Ag Combination of a cbp/p300 bromodomain inhibitor and a kras inhibitor for the treatment of cancer
BR112023020538A2 (pt) 2021-04-07 2024-01-23 Tolremo Therapeutics Ag Derivados heterocíclicos, composições farmacêuticas e seus usos no tratamento ou na melhoria de câncer
CN120769855A (zh) * 2022-11-03 2025-10-10 生物衔接医疗公司 4-氨基吡咯并[2,1-f][1,2,4]三嗪及其制备和用途
WO2024220399A1 (en) * 2023-04-17 2024-10-24 Bristol-Myers Squibb Company Pyrazolotriazinecarbonitriles useful as kinase inhibitors
WO2025074096A1 (en) * 2023-10-02 2025-04-10 Turbine Simulated Cell Technologies Ltd P97 (vcp) atpase inhibitors
WO2025193691A1 (en) * 2024-03-12 2025-09-18 Casma Therapeutics, Inc. Bicyclic heteroaromatic compounds as trpml modulators

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4327027A1 (de) 1993-02-15 1994-08-18 Bayer Ag Imidazoazine
TWI312347B (en) 2001-02-08 2009-07-21 Eisai R&D Man Co Ltd Bicyclic nitrogen-containing condensed ring compounds
MY145634A (en) 2003-12-29 2012-03-15 Bristol Myers Squibb Co Pyrrolotriazine compounds as kinase inhibitors
WO2006065788A2 (en) 2004-12-13 2006-06-22 Glaxo Group Limited Novel muscarinic acetylcholine receptor antagonists
WO2006065755A2 (en) 2004-12-13 2006-06-22 Glaxo Group Limited Quaternary ammonium salts of fused hetearomatic amines as novel muscarinic acetylcholine receptor antagonists
US7723336B2 (en) 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US20070078136A1 (en) 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
CN101312977B (zh) * 2005-09-22 2012-06-13 布里斯托尔-迈尔斯.斯奎布公司 用作激酶调节剂的稠合杂环化合物
WO2008057402A2 (en) 2006-11-02 2008-05-15 Cytovia, Inc. N-aryl-isoxazolopyrimidin-4-amines and related compounds as activators of caspases and inducers of apoptosis and the use thereof
EP2125819B1 (en) * 2007-03-21 2014-10-22 Bristol-Myers Squibb Company Fused heterocyclic compounds useful for the treatment of proliferative, allergic, autoimmune or inflammatory diseases
US8476430B2 (en) 2008-07-24 2013-07-02 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
TWI491610B (zh) 2008-10-09 2015-07-11 必治妥美雅史谷比公司 作為激酶抑制劑之咪唑并嗒腈
WO2010068810A2 (en) 2008-12-10 2010-06-17 Cgi Pharmaceuticals, Inc. Certain substituted amides, method of making, and method of use thereof
US20110071115A1 (en) * 2009-09-11 2011-03-24 Cylene Pharmaceuticals, Inc. Pharmaceutically useful heterocycle-substituted lactams
CN102762208A (zh) * 2009-12-04 2012-10-31 赛林药物股份有限公司 作为ck2抑制剂的吡唑嘧啶和相关杂环
EP2526102B1 (en) 2010-01-22 2017-03-08 Fundación Centro Nacional de Investigaciones Oncológicas Carlos III Inhibitors of PI3 kinase
US20130131057A1 (en) 2010-05-13 2013-05-23 Centro Nacional De Investigaciones Oncologicas (Cnio New bicyclic compounds as pi3-k and mtor inhibitors
TW201414737A (zh) 2012-07-13 2014-04-16 必治妥美雅史谷比公司 作爲激酶抑制劑之咪唑并三□甲腈

Similar Documents

Publication Publication Date Title
JP2015524798A5 (https=)
US11197858B2 (en) Substituted amines for treating cardiac diseases
US11129832B2 (en) Biheteroaryl compounds and uses thereof
JP6228199B2 (ja) キナーゼ阻害剤として有用であるイミダゾトリアジンカルボニトリル
CN116323623B (zh) 作为SOS1抑制剂的吡啶并[2,3-d]嘧啶-4-胺
KR101843600B1 (ko) 트리아진-옥사디아졸
ES2727376T3 (es) Derivados de aminotriazina útiles como compuestos inhibidores de quinasa de unión TANK
CN102596913B (zh) 大麻素受体调节剂
EP3788040A1 (en) Pyridazinones as parp7 inhibitors
RU2018105684A (ru) Замещенные трициклические соединения и способ применения
JP2018530557A5 (https=)
TW201722948A (zh) N-磺醯化吡唑并﹝3,4-b﹞吡啶-6-甲醯胺及其使用方法
EP2852584A1 (en) Substituted dipyridylamines and uses thereof
JP2018522929A5 (https=)
JP2018530557A (ja) 置換ピラゾロ[3,4−b]ピリジン−6−カルボン酸およびこの使用
US20160159773A1 (en) Heterocyclic compound
US20180155285A1 (en) 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones
EP3317279B1 (en) Triaza-spirodecanones as ddr1 inhibitors
JP2017531672A5 (https=)
JP2024009891A (ja) T型カルシウムチャネル阻害剤
EP3950059A1 (en) Use of t-type calcium channel blocker for treating pruritus